These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16522281)

  • 1. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
    Trost S; Pratley R; Sobel B
    Curr Diab Rep; 2006 Feb; 6(1):47-54. PubMed ID: 16522281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glycemic control and other determinants on vascular disease in type 2 diabetes.
    Sobel BE
    Am J Med; 2002 Oct; 113 Suppl 6A():12S-22S. PubMed ID: 12431758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1.
    Skurk T; Hauner H
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1357-64. PubMed ID: 15356668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise, fitness, and cardiovascular disease risk in type 2 diabetes and the metabolic syndrome.
    Duncan GE
    Curr Diab Rep; 2006 Feb; 6(1):29-35. PubMed ID: 16522278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
    Mavri A; Alessi MC; Juhan-Vague I
    J Intern Med; 2004 Apr; 255(4):448-56. PubMed ID: 15049879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance syndrome: interaction with coagulation and fibrinolysis.
    Kohler HP
    Swiss Med Wkly; 2002 May; 132(19-20):241-52. PubMed ID: 12148078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients.
    Schneider DJ; Nordt TK; Sobel BE
    Diabetes; 1993 Jan; 42(1):1-7. PubMed ID: 8420806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
    Palumbo PJ
    J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
    Festa A; Williams K; Tracy RP; Wagenknecht LE; Haffner SM
    Circulation; 2006 Apr; 113(14):1753-9. PubMed ID: 16585388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
    Nordt TK; Schneider DJ; Sobel BE
    Circulation; 1994 Jan; 89(1):321-30. PubMed ID: 8281664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PAI-1, the primary plasmatic inhibitor of fibrinolysis. Physiopathologic role and molecular mechanisms].
    Banfi C; Mussoni L; Tremoli E
    Minerva Endocrinol; 2002 Sep; 27(3):181-91. PubMed ID: 12091793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 diabetes mellitus in adolescence: lipid and cardiovascular risk factors.
    Jones KL; Dewan AK
    Curr Diab Rep; 2003 Jun; 3(3):255-62. PubMed ID: 12762975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes.
    Sobel BE; Schneider DJ
    Cardiol Clin; 2004 Nov; 22(4):511-26. PubMed ID: 15501620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
    Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
    Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinogen, fibrinolysis and diabetes mellitus: a comment.
    Vague P; Juhan-Vague I
    Diabetologia; 1997 Jun; 40(6):738-40. PubMed ID: 9222657
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia.
    Reaven GM
    Diabetes Obes Metab; 2002 Jan; 4 Suppl 1():S13-8. PubMed ID: 11843950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.